'Severe atopic dermatitis drug too expensive for adolescents'

Korea Biomedical Review

21 July 2020 - The drug regulator expanded approval for Dupixent (dupilumab), a treatment for severe atopic dermatitis, from adults to adolescents aged 12 or more. However, the drug's high cost makes it difficult for adolescent patients to get the treatment, patients said.

The government allowed health insurance benefits for Dupixent in adults with atopic dermatitis in January. It broadened the scope of approval from adults to adults and adolescents aged 12 or more.

However, adolescent patients cannot get the insurance benefit, meaning that they have to pay the drug's full price.

Read Korean Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder